tiprankstipranks
Trending News
More News >

PanGenomic Health Releases 2024 Financial Results

Story Highlights
PanGenomic Health Releases 2024 Financial Results

Elevate Your Investing Strategy:

An announcement from PanGenomic Health, Inc. Class A ( (TSE:NARA) ) is now available.

PanGenomic Health Inc. has announced the filing of its audited annual consolidated financial statements for the fiscal year ending December 31, 2024. This announcement marks a significant step in the company’s operations, as it continues to focus on providing personalized health solutions through its digital platform. The financial results are available on the company’s profile at sedarplus.ca, reflecting its ongoing commitment to transparency and stakeholder engagement.

Spark’s Take on TSE:NARA Stock

According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.

The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.

To see Spark’s full report on TSE:NARA stock, click here.

More about PanGenomic Health, Inc. Class A

PanGenomic Health is a precision health company focused on developing a self-care digital platform that provides personalized, evidence-based information on natural treatments, primarily supporting mental health. As a British Columbia benefit company, its mission is to enhance health and wellness through technology that offers plant-based solutions tailored to individual health profiles.

Average Trading Volume: 14,903

Technical Sentiment Signal: Buy

Current Market Cap: C$4.48M

See more insights into NARA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1